Diabetes treatment is evolving rapidly with multiple breakthroughs. Eli Lilly’s orforglipron demonstrated robust weight and A1C reductions in Phase III trials, positioning it as a strong oral GLP-1 contender. Editas Medicine pivoted toward an in vivo gene editing candidate (EDIT-401) aimed at hyperlipidemia via LDLR gene editing with potential one-time LDL cholesterol control. Continuous Glucose Monitoring (CGM) technologies show promise in improving management and outcomes, especially for aging diabetic populations. These strides reflect a comprehensive, multi-pronged approach targeting glycemic control, metabolic health, and patient convenience.